Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 787-795

  Kawano, Takeshi ^a   Akiyama, Masaharu ^a,b   Agawa Ohta, Miyuki ^a   Mikami Terao, Yoko ^a,b   Iwase, Satsuki ^a   Yanagisawa, Takaaki ^c   Ida, Hiroyuki ^b   Agata, Naoki ^a   Yamada, Hisashi ^a  

^a Institute of DNA Medicine   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Histone deacetylase inhibitor; p53; Retinoblastoma

Indexed keywords

CASPASE 3; DEPSIPEPTIDE; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; ROMIDEPSIN; VALPROIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RADIOSENSITIZATION; RETINOBLASTOMA;

EID: 77956526861     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000728     Document Type: Article

References (28)

1. Shields CL, Meadows AT, Leahey AM and Shields JA: Continuing challenges in the management of retinoblastoma with chemotherapy. Retina 24: 849-862, 2004.
2. Yanagisawa T: Systemic chemotherapy as a new conservative treatment for intraocular retinoblastoma. Int J Clin Oncol 9: 13-24, 2004.
3. Suzuki S and Kaneko A: Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 9: 1-6, 2004.
4. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
5. Nork TM, Poulsen GL, Millecchia LL, Jantz RG and Nickells RW: p53 regulates apoptosis in human retinoblastoma. Cancer Res 115: 213-219, 1997.
6. waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastoma. Cancer Res 61: 3157-3163, 2001.
7. Appella E and Anderson CW: Post-translational modifications and activation of p53 by genotoxic stress. Eur J Biochem 268: 2764-2772, 2001. (Pubitemid 32862957)
8. Shangary S and Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14: 5318-5324, 2008.
9. Marine JCW, Dyer MA and Jochemsen AG: MDMX: from bench to bedside. J Cell Sci 120: 371-378, 2007.
10. Wade M and Wahl GM: Targeting mdm2 and mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1-11, 2009.
11. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Galindo CR, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG and Dyer MA: Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66, 2006.
12. Monneret C: Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13, 2005.
13. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001.
14. Wolff JEA, Kramm C, Kortmann RD, Pietsch T, Rutkowwski S, Jorch N, Gnekow A and Driever PH: Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 90: 309-314, 2008.
15. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M and Horinouchi S: FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921, 2002.
16. Konstantinopoulos PA, Vandoros GP and Papavassiliou AG: FK228 (depsipeptide): a HDAC inhibitor with pleiotropic anti-tumor activities. Cancer Chemother Pharmacol 58: 711-715, 2006.
17. Dalgard CL, Quill KRV and O'Brien JM: Evaluation of the in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 14: 3113-3123, 2008.
18. Shrivastav M, Haro LPD and Nickoloff JA: Regulation of DNA double-strand break repair pathway choice. Cell Res 18: 134-147, 2008.
19. Camphausen K, Burgan W, Cerre M, Oswald KA, Trepel JB, Lee MJ and Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64: 316-321, 2004.
20. Zhang Y, Adachi M, Zou H, Hareyama M, Imai K and Shinomura Y: Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys 65: 859-866, 2006. (Pubitemid 43795847)
21. Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K and Tofilon PJ: Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14: 5410-5415, 2008.
22. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM and Meyn RE: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol Cancer Ther 5: 1967-1974, 2006.
23. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY and Chen CS: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67: 5318-5327, 2007.
24. Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
25. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Gene Dev 15: 2831-2841, 1998.
26. Vasudev K, Das S, Goswami U and Tayal G: Pharmacokinetics of valproic acid in patients with bipolar disorder. J Psychopharmacol 15: 187-190, 2001.
27. Spiller HA, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, Sollee DR, Bangh SA and Griffith JR: Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 38: 755-760, 2000. (Pubitemid 32047302)
28. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chen KK, Goldspiel B, Fojo AT, Balcerzak SP and Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728, 2002.